Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 01:32PM ET
3.23
Dollar change
+0.13
Percentage change
4.35
%
Index- P/E- EPS (ttm)-0.18 Insider Own12.12% Shs Outstand10.30M Perf Week-8.62%
Market Cap33.90M Forward P/E- EPS next Y- Insider Trans1.44% Shs Float9.21M Perf Month-7.83%
Income-1.84M PEG- EPS next Q- Inst Own41.17% Short Float0.04% Perf Quarter45.07%
Sales13.54M P/S2.50 EPS this Y- Inst Trans1.02% Short Ratio0.13 Perf Half Y89.18%
Book/sh0.82 P/B3.93 EPS next Y- ROA-15.37% Short Interest0.00M Perf Year163.01%
Cash/sh0.44 P/C7.34 EPS next 5Y- ROE-22.92% 52W Range0.95 - 4.04 Perf YTD-6.50%
Dividend Est.- P/FCF38.97 EPS past 5Y-39.13% ROI-20.23% 52W High-19.99% Beta1.35
Dividend TTM- Quick Ratio3.41 Sales past 5Y20.38% Gross Margin56.42% 52W Low240.53% ATR (14)0.23
Dividend Ex-Date- Current Ratio4.65 EPS Y/Y TTM75.79% Oper. Margin-12.09% RSI (14)41.42 Volatility10.94% 5.84%
Employees27 Debt/Eq0.09 Sales Y/Y TTM32.18% Profit Margin-13.58% Recom2.00 Target Price4.50
Option/ShortNo / Yes LT Debt/Eq0.05 EPS Q/Q94.45% Payout- Rel Volume0.28 Prev Close3.10
Sales Surprise11.20% EPS Surprise69.23% Sales Q/Q55.33% EarningsNov 08 AMC Avg Volume32.08K Price3.23
SMA20-8.48% SMA50-6.82% SMA20053.37% Trades Volume6,932 Change4.35%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated B. Riley Securities Buy $12.50
Nov-11-23 12:41PM
Nov-08-23 04:15PM
Nov-01-23 07:30AM
Oct-25-23 07:30AM
Sep-19-23 04:30PM
04:15PM Loading…
Aug-09-23 04:15PM
Jul-26-23 07:30AM
May-24-23 07:30AM
May-10-23 04:15PM
May-08-23 07:30AM
Apr-26-23 07:30AM
Apr-04-23 07:30AM
Mar-08-23 04:15PM
Mar-01-23 04:30PM
Feb-22-23 04:30PM
07:30AM Loading…
Jan-11-23 07:30AM
Nov-02-22 04:15PM
Oct-19-22 07:30AM
Oct-12-22 07:30AM
Oct-11-22 07:30AM
Sep-28-22 07:30AM
Sep-08-22 04:00PM
Aug-13-22 08:22AM
Aug-10-22 04:15PM
Jul-27-22 07:30AM
Jul-06-22 07:30AM
May-17-22 07:30AM
May-04-22 04:15PM
Apr-27-22 07:30AM
Apr-26-22 07:30AM
07:30AM Loading…
Mar-21-22 07:30AM
Feb-28-22 07:30AM
Feb-23-22 04:15PM
Feb-09-22 07:30AM
Jan-13-22 07:30AM
Jan-11-22 07:30AM
Nov-23-21 04:15PM
Nov-08-21 07:30AM
Nov-04-21 04:15PM
Oct-21-21 07:30AM
Oct-08-21 07:30AM
Oct-05-21 07:30AM
Sep-15-21 09:39AM
Sep-06-21 11:42AM
Sep-01-21 07:30AM
Aug-05-21 04:15PM
Jul-28-21 03:03PM
Jul-12-21 07:30AM
Jul-09-21 04:18PM
Jul-08-21 11:20AM
07:30AM
05:07AM
Jun-29-21 08:50AM
Jun-23-21 09:35AM
May-31-21 08:50AM
May-06-21 04:15PM
02:45PM
Apr-26-21 07:30AM
Apr-09-21 05:29AM
Apr-05-21 07:30AM
Mar-16-21 07:45AM
Mar-10-21 07:30AM
Mar-04-21 02:07AM
Mar-01-21 04:15PM
02:30PM
Feb-22-21 07:30AM
Feb-18-21 07:30AM
Jan-22-21 02:21AM
Jan-12-21 07:30AM
Jan-05-21 10:55AM
Jan-04-21 07:30AM
Nov-29-20 09:33AM
Nov-19-20 06:45AM
Nov-09-20 07:30AM
Nov-05-20 04:27PM
02:30PM
Oct-29-20 07:30AM
Oct-24-20 10:47AM
Oct-16-20 07:30AM
Oct-13-20 07:30AM
Oct-07-20 07:30AM
Oct-06-20 07:30AM
Aug-31-20 05:00PM
Aug-25-20 07:30AM
Aug-14-20 07:30AM
Aug-06-20 01:43PM
Aug-05-20 04:15PM
Jul-29-20 07:30AM
Jul-22-20 07:30AM
Jul-16-20 11:00AM
Jul-14-20 07:30AM
Jul-13-20 07:30AM
Jul-08-20 07:30AM
Jun-18-20 07:30AM
Jun-10-20 01:44PM
Jun-03-20 09:00AM
Jun-02-20 07:30AM
May-11-20 04:15PM
May-06-20 04:15PM
Apr-29-20 07:30AM
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Banks Robert R. Jr.President and CEODec 07Buy2.2018,00039,64720,000Dec 11 04:17 PM
Banks Robert R. Jr.President and CEOAug 15Buy1.691,9013,2072,000Aug 15 04:15 PM
Banks Robert R. Jr.President and CEOAug 14Buy1.509914899Aug 15 04:15 PM